{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:21:45Z","timestamp":1790972505227,"version":"4.1.0"},"reference-count":57,"publisher":"Public Library of Science (PLoS)","issue":"4","content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0017626","type":"journal-article","created":{"date-parts":[[2011,4,22]],"date-time":"2011-04-22T20:49:54Z","timestamp":1303505394000},"page":"e17626","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":35,"title":["Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation"],"prefix":"10.1371","volume":"6","author":[{"given":"Rolf","family":"Burghaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Coboeken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gaub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Kuepfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Sensse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Ulrich","family":"Siegmund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Mueck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Lippert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,4,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/01.ATV.0000046238.23903.FC","article-title":"The dynamics of thrombin formation.","volume":"23","author":"KG Mann","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"<italic>In vitro<\/italic> and <italic>in vivo<\/italic> studies of the novel antithrombotic agent BAY 59-7939 \u2013 an oral, direct Factor Xa inhibitor.","volume":"3","author":"E Perzborn","year":"2005","journal-title":"J Thromb Haemost"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.","volume":"78","author":"D Kubitza","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition).","volume":"133","author":"J Ansell","year":"2008","journal-title":"Chest"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"141S","DOI":"10.1378\/chest.08-0689","article-title":"Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition).","volume":"133","author":"J Hirsh","year":"2008","journal-title":"Chest"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1517\/13543784.15.8.843","article-title":"Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.","volume":"15","author":"D Kubitza","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1055\/s-2005-916162","article-title":"Mechanism of action of the oral direct thrombin inhibitor ximelagatran.","volume":"5","author":"C Mattsson","year":"2005","journal-title":"Semin Vasc Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1177\/1076029609343004","article-title":"Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.","volume":"15","author":"J Stangier","year":"2009","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/imammb\/20.1.105","article-title":"A mathematical model of lipid-mediated thrombin generation.","volume":"20","author":"SD Bungay","year":"2003","journal-title":"Math Med Biol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"18322","DOI":"10.1074\/jbc.M201173200","article-title":"A model for the stoichiometric regulation of blood coagulation.","volume":"277","author":"MF Hockin","year":"2002","journal-title":"J Biol Chem"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0049-3848(00)00405-9","article-title":"Analysis of the activated partial thromboplastin time test using mathematical modeling.","volume":"101","author":"AE Kogan","year":"2001","journal-title":"Thromb Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1111\/j.1538-7836.2005.01592.x","article-title":"Mathematical and biological models of blood coagulation.","volume":"3","author":"T Orfeo","year":"2005","journal-title":"J Thromb Haemost"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0006-3495(01)76085-7","article-title":"Surface-mediated control of blood coagulation: the role of binding site densities and platelet deposition.","volume":"80","author":"AL Kuharsky","year":"2001","journal-title":"Biophys J"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/10273660412331317415","article-title":"A model incorporating some of the mechanical and biochemical factors underlying clot formation and dissolution in flowing blood.","volume":"5","author":"M Anand","year":"2003","journal-title":"J Theor Med"},{"key":"ref15","article-title":"MoBi\u00ae.","year":"2009"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"8062","DOI":"10.1074\/jbc.271.14.8062","article-title":"Calcium ion modulation of meizothrombin autolysis at Arg55-Asp56 and catalytic activity.","volume":"271","author":"WK Stevens","year":"1996","journal-title":"J Biol Chem"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0021-9258(19)40122-1","article-title":"Binding of human factor VIII to phospholipid vesicles.","volume":"265","author":"GE Gilbert","year":"1990","journal-title":"J Biol Chem"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0167-4838(82)90307-7","article-title":"Inhibition of human factor Xa by various plasma protease inhibitors.","volume":"701","author":"V Ellis","year":"1982","journal-title":"Biochim Biophys Acta"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1182\/blood.V91.5.1542","article-title":"Protein C inhibitor acts as a procoagulant by inhibiting the thrombomodulin-induced activation of protein C in human plasma.","volume":"91","author":"MG Elisen","year":"1998","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"17606","DOI":"10.1016\/S0021-9258(19)47415-2","article-title":"Identification of divalent metal ion-dependent inhibition of activated protein C by alpha 2-macroglobulin and alpha 2-antiplasmin in blood and comparisons to inhibition of factor Xa, thrombin, and plasmin.","volume":"266","author":"MJ Heeb","year":"1991","journal-title":"J Biol Chem"},{"issue":"Pt 1","key":"ref21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1042\/bj2950239","article-title":"Interaction of activated protein C with serpins.","volume":"295","author":"JM Hermans","year":"1993","journal-title":"Biochem J"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1055\/s-0038-1646897","article-title":"A second plasma inhibitor of activated protein C: alpha 1-antitrypsin.","volume":"62","author":"FJ van der Meer","year":"1989","journal-title":"Thromb Haemost"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/oxfordjournals.jbchem.a134583","article-title":"Mechanism of inhibition of activated protein C by protein C inhibitor.","volume":"95","author":"K Suzuki","year":"1984","journal-title":"J Biochem"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1050-1738(00)00019-0","article-title":"Role of activation of the coagulation factor VIII in interaction with vWf, phospholipid, and functioning within the factor Xase complex.","volume":"9","author":"EL Saenko","year":"1999","journal-title":"Trends Cardiovasc Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/ATVBAHA.110.202978","article-title":"Rivaroxaban: a new oral factor Xa inhibitor.","volume":"30","author":"E Perzborn","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00003088-200847030-00006","article-title":"Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopaedic surgery.","volume":"47","author":"W Mueck","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1055\/s-0037-1613550","article-title":"DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins.","volume":"89","author":"AR Rezaie","year":"2003","journal-title":"Thromb Haemost"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1538-7836.2004.01081.x","article-title":"First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.","volume":"3","author":"JH Alexander","year":"2005","journal-title":"J Thromb Haemost"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1055\/s-0038-1642436","article-title":"DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa.","volume":"71","author":"T Hara","year":"1994","journal-title":"Thromb Haemost"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1538-7933.2004.00649.x","article-title":"Synthetic selective inhibitors of coagulation Factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis.","volume":"2","author":"M Ieko","year":"2004","journal-title":"J Thromb Haemost"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0009-9236(99)70033-0","article-title":"Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers.","volume":"66","author":"N Murayama","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"50439","DOI":"10.1074\/jbc.M208222200","article-title":"Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation.","volume":"277","author":"H Nagashima","year":"2002","journal-title":"J Biol Chem"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1046\/j.1538-7836.2003.00127.x","article-title":"Predicting the pharmacology of thrombin inhibitors.","volume":"1","author":"TE Adams","year":"2003","journal-title":"J Thromb Haemost"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0049-3848(03)00249-4","article-title":"The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review.","volume":"109","author":"D Gustafsson","year":"2003","journal-title":"Thromb Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clpt.2004.11.001","article-title":"Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis.","volume":"77","author":"M Cullberg","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1055\/s-0037-1616094","article-title":"Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample.","volume":"86","author":"C Mattsson","year":"2001","journal-title":"Thromb Haemost"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00228-003-0565-7","article-title":"Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.","volume":"59","author":"UG Eriksson","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"ref38","article-title":"Lovenox (enoxaparin sodium) Prescribing Information.","year":"2009"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1055\/s-2003-44457","article-title":"Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions.","volume":"3","author":"AK Wittkowsky","year":"2003","journal-title":"Semin Vasc Med"},{"key":"ref40","article-title":"Thromboplastin correlation study.","year":"1999"},{"key":"ref41","article-title":"Vergleichbarkeit der Methoden zur Bestimmung der Aktivierten Partiellen Thromboplastinzeit und der Resistenz gegen aktivertes Protein C.","author":"G Kappert","year":"2002"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/107602960300900101","article-title":"Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use.","volume":"9","author":"M Tobu","year":"2003","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0167-4838(98)00120-4","article-title":"Mechanism of factor IXa inhibition by antithrombin in the presence of unfractionated and low molecular weight heparins and fucoidan.","volume":"1387","author":"S Mauray","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1055\/s-0038-1646603","article-title":"The action of a synthetic pentasaccharide on thrombin generation in whole plasma.","volume":"61","author":"S Beguin","year":"1989","journal-title":"Thromb Haemost"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1046\/j.1538-7836.2003.00254.x","article-title":"Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex.","volume":"1","author":"N Brufatto","year":"2003","journal-title":"J Thromb Haemost"},{"key":"ref46","article-title":"Clexane\u00ae and Clexane\u00ae Forte.","year":"2010"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00001721-200203000-00008","article-title":"Evaluation of the blood coagulation mechanism and platelet aggregation in individuals with mechanical or biological heart prostheses.","volume":"13","author":"CN Ferreira","year":"2002","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1538-7836.2005.01657.x","article-title":"Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.","volume":"4","author":"BI Eriksson","year":"2006","journal-title":"J Thromb Haemost"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/j.1538-7836.2005.01602.x","article-title":"BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.","volume":"3","author":"AGG Turpie","year":"2005","journal-title":"J Thromb Haemost"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1161\/CIRCULATIONAHA.106.642074","article-title":"A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.","volume":"114","author":"BI Eriksson","year":"2006","journal-title":"Circulation"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.","volume":"358","author":"BI Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.","volume":"372","author":"AK Kakkar","year":"2008","journal-title":"Lancet"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.","volume":"358","author":"MR Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.","volume":"373","author":"AGG Turpie","year":"2009","journal-title":"Lancet"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study.","volume":"116","author":"G Agnelli","year":"2007","journal-title":"Circulation"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2008-05-160143","article-title":"A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study.","volume":"112","author":"HR Buller","year":"2008","journal-title":"Blood"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11239-007-0108-7","article-title":"New oral Xa and IIa inhibitors: updates on clinical trial results.","volume":"25","author":"S Haas","year":"2008","journal-title":"J Thromb Thrombolysis"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0017626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T01:17:02Z","timestamp":1637543822000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0017626"}},"subtitle":[],"editor":[{"given":"Vladimir N.","family":"Uversky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,4,22]]},"references-count":57,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2011,4,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0017626","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,22]]}}}